| Literature DB >> 27686017 |
Susanna Naggie1, Andrew J Muir1.
Abstract
The current standard of care for the treatment of hepatitis C virus (HCV) consists of interferon-free direct-acting antiviral (DAA) regimens, including combinations of DAAs and fixed-dose combination pills. DAAs for HCV are likely to be heralded as one of medicine's greatest advancements. Viral eradication rates are pushing 100% for many HCV-infected populations, including patients with HIV/HCV coinfection, decompensated cirrhosis, liver and kidney transplants, and end-stage liver disease. We highlight the greatest successes of combination DAA therapies, discuss the ongoing challenges, and identify the remaining patient subgroups with unmet medical needs.Entities:
Keywords: HCV, direct-acting antiviral, HIV/HCV coinfection; decompensated cirrhosis, liver transplant; end-stage liver disease; kidney transplant
Mesh：
Substances：
Year: 2016 PMID： 27686017 DOI： 10.1146/annurev-med-052915-015720
Source DB: PubMed Journal: Annu Rev Med ISSN： 0066-4219 Impact factor: 13.739